Reversible cerebral vasoconstriction syndrome in a patient taking citalopram and Hydroxycut: A case report

Journal of Medical Case Reports

Volumn 5, Issue , 2011, Pages

  Cvetanovich, Gregory L ^a   Ramakrishnan, Pankajavalli ^a   Klein, Joshua P ^a   Rao, Vikram R ^a   Ropper, Allan H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; HERBACEOUS AGENT; HYDROXYCUT; LISINOPRIL; NIMODIPINE; PREDNISONE; SIMVASTATIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; BRAIN ARTERY; CASE REPORT; CAUCASIAN; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; DIET SUPPLEMENTATION; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVERSIBLE CEREBRAL VASOCONSTRICTION SYNDROME; TREATMENT OUTCOME;

EID: 84855971529     PISSN: None     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-5-548     Document Type: Article

References (18)

1. Narrative review: reversible cerebral vasoconstriction syndromes. Calabrese LH, Dodick DW, Schwedt TJ, Singhal AB, Ann Intern Med 2007 146 1 34 44 17200220 (Pubitemid 351650319)
2. Postpartum angiopathy and other cerebral vasoconstriction syndromes. Singhal AB, Bernstein RA, Neurocrit Care 2005 3 1 91 97 10.1385/NCC:3:1:091 16159105 (Pubitemid 41278403)
3. Nimodipine for treatment of primary thunderclap headache. Lu SR, Liao YC, Fuh JL, Lirng JF, Wang SJ, Neurology 2004 62 8 1414 1416 15111686
4. Reversible segmental cerebral vasoconstriction (Call-Fleming syndrome): the role of calcium antagonists. Dodick DW, Cephalalgia 2003 23 3 163 165 10.1046/j.1468-2982.2003.00506.x 12662181 (Pubitemid 36461383)
5. Postpartum angiopathy with reversible posterior leukoencephalopathy. Singhal AB, Arch Neurol 2004 61 3 411 416 10.1001/archneur.61.3.411 15023819 (Pubitemid 38327360)
6. Benign angiopathy of the central nervous system: cohort of 16 patients with clinical course and long-term followup. Hajj-Ali RA, Furlan A, Abou-Chebel A, Calabrese LH, Arthritis Rheum 2002 47 6 662 669 10.1002/art.10797 12522842 (Pubitemid 35461321)
7. Diffuse cerebral vasoconstriction (Call-Fleming syndrome) and stroke associated with antidepressants. Noskin O, Jafarimojarrad E, Libman RB, Nelson JL, Neurology 2006 67 1 159 160 10.1212/01.wnl.0000223648.76430.27 16832100 (Pubitemid 44305485)
8. Reversible cerebral vasoconstriction syndrome: case report. Oz O, Demirkaya S, Bek S, Eroglu E, Ulas UH, Odabasi Z, J Headache Pain 2009 10 4 295 298 10.1007/s10194-009-0117-3 19370308
9. Cerebral vasculitis and hemorrhage in an adolescent taking diet pills containing phenylpropanolamine: case report and review of literature. Forman HP, Levin S, Stewart B, Patel M, Feinstein S, Pediatrics 1989 83 5 737 741 2654866 (Pubitemid 19120517)
10. FDA Warns Consumers to Stop Using Hydroxycut Products Risk of Liver Injury. http://www.fda.gov/downloads/NewsEvents/PublicHealthFocus/UCM155660.pdf
11. Hepatoxicity associated with weight-loss supplements: a case for better post-marketing surveillance. Lobb A, World J Gastroenterol 2009 15 14 1786 1787 10.3748/wjg.15.1786 19360927
12. Sales of Supplements Containing Ephedrine Alkaloids (Ephedra) Prohibited. http://web.archive.org/web/20080126150250/www.fda.gov/oc/initiatives/ephedra/ february2004/
13. Hepatotoxicity due to hydroxycut: a case series. Fong TL, Klontz KC, Canas-Coto A, Casper SJ, Durazo FA, Davern TJ, Hayashi P, Lee WM, Seeff LB, Am J Gastroenterol 2010 105 7 1561 1566 10.1038/ajg.2010.5 20104221
14. Rhabdomyolysis associated with the nutritional supplement Hydroxycut. Dehoney S, Wellein M, Am J Health Syst Pharm 2009 66 2 142 148 10.2146/ajhp070640 19139478
15. Hypertensive retinopathy associated with use of the ephedra-free weight-loss herbal supplement Hydroxycut. Willis SL, Moawad FJ, Hartzell JD, Iglesias M, Jackson WL, MedGenMed 2006 8 3 82 17406200
16. FDA Warning on Hydroxycut Products. http://www.fda.gov/ForConsumers/ ConsumerUpdates/ucm152152.htm
17. Hydroxycut ingredient list. http://www.hydroxycutadvanced.com/
18. The effect of daily caffeine use on cerebral blood flow: How much caffeine can we tolerate? Addicott MA, Yang LL, Peiffer AM, Burnett LR, Burdette JH, Chen MY, Hayasaka S, Kraft RA, Maldjian JA, Laurienti PJ, Hum Brain Mapp 2009 30 10 3102 3114 10.1002/hbm.20732 19219847